Rakuten Securities Inc. Purchases Shares of 805 TransMedics Group, Inc. (NASDAQ:TMDX)

Rakuten Securities Inc. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDXFree Report) during the third quarter, HoldingsChannel reports. The firm purchased 805 shares of the company’s stock, valued at approximately $126,000.

Other hedge funds also recently modified their holdings of the company. Entropy Technologies LP grew its position in shares of TransMedics Group by 34.7% in the 3rd quarter. Entropy Technologies LP now owns 10,471 shares of the company’s stock valued at $1,644,000 after buying an additional 2,700 shares during the last quarter. WCM Investment Management LLC acquired a new position in shares of TransMedics Group in the third quarter worth approximately $8,720,000. Venturi Wealth Management LLC boosted its holdings in TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the last quarter. Jag Capital Management LLC acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $208,000. Finally, Chartwell Investment Partners LLC acquired a new stake in TransMedics Group during the 3rd quarter valued at approximately $662,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,958 shares of company stock worth $5,230,528. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $89.11 on Tuesday. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of 94.80 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a fifty-two week low of $56.83 and a fifty-two week high of $177.37. The firm’s 50-day simple moving average is $130.45 and its 200 day simple moving average is $139.89.

TransMedics Group (NASDAQ:TMDXGet Free Report) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the business earned ($0.12) EPS. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, research analysts anticipate that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Oppenheimer reduced their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Robert W. Baird lowered their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group reduced their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Finally, Needham & Company LLC dropped their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $144.80.

Check Out Our Latest Analysis on TransMedics Group

TransMedics Group Company Profile

(Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

See Also

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDXFree Report).

Institutional Ownership by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.